RhumbLine Advisers’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-68,062
| Closed | -$5.12M | – | 3092 |
|
|
2022
Q2 | $5.12M | Buy |
68,062
+8,552
| +14% | +$380K | 0.01% | 1229 |
|
|
2022
Q1 | $1.6M | Sell |
59,510
-4,644
| -7% | -$156K | ﹤0.01% | 1922 |
|
|
2021
Q4 | $3.06M | Sell |
64,154
-1,615
| -2% | -$72.2K | ﹤0.01% | 1640 |
|
|
2021
Q3 | $4.37M | Buy |
65,769
+1,773
| +3% | +$126K | 0.01% | 1436 |
|
|
2021
Q2 | $4.99M | Buy |
63,996
+20,541
| +47% | +$1.52M | 0.01% | 1427 |
|
|
2021
Q1 | $4.11M | Sell |
43,455
-3,366
| -7% | -$400K | 0.01% | 1518 |
|
|
2020
Q4 | $5.71M | Buy |
46,821
+5,881
| +14% | +$644K | 0.01% | 1281 |
|
|
2020
Q3 | $3.58M | Sell |
40,940
-1,540
| -4% | -$107K | 0.01% | 1358 |
|
|
2020
Q2 | $2.74M | Buy |
42,480
+6,091
| +17% | +$351K | ﹤0.01% | 1554 |
|
|
2020
Q1 | $1.63M | Buy |
36,389
+2,555
| +8% | +$136K | ﹤0.01% | 1655 |
|
|
2019
Q4 | $2.11M | Buy |
33,834
+27,105
| +403% | +$1.29M | ﹤0.01% | 1775 |
|
|
2019
Q3 | $253K | Buy |
6,729
+911
| +16% | +$39.7K | ﹤0.01% | 2659 |
|
|
2019
Q2 | $237K | Buy |
+5,818
| New | +$208K | ﹤0.01% | 2721 |
|
RhumbLine Advisers's TPTX Position: Q3 2022 in Review
RhumbLine Advisers sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 68,062 shares — an estimated $5.12M sold.
RhumbLine Advisers first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $5.71M in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- RhumbLine Advisers reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- RhumbLine Advisers sold 68,062 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $5.12M.
- RhumbLine Advisers first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- RhumbLine Advisers's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.71M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on RhumbLine Advisers's 13F filing for Q3 2022, filed 10 Nov 2022.